Procter & Gamble Pharmaceuticals -- P&GP -- Selects EMAX Substance Manager as Inventory Management Solution for Discovery Operations.Business Editors/Hi-Tech Writers NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Oct. 24, 2000 Ability to Integrate Diverse Robotics robotics, science and technology of general purpose, programmable machine systems. Contrary to the popular fiction image of robots as ambulatory machines of human appearance capable of performing almost any task, most robotic systems are anchored to fixed positions and Data Sources Are Key Selection Factors EMAX EMAX Email Address Exchange Service Solutions, a SciQuest company (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SQST) and a leading provider of e-Research asset management solutions to the life sciences industry, today announced that Procter & Gamble Corporation (NYSE NYSE See: New York Stock Exchange :PG) has selected EMAX Substance Manager software for use in its pharmaceutical research operations. EMAX Substance Manager is an integrated compound and plate management solution that speeds discovery by providing researchers with tools and information to manage the entire life cycle of proprietary compounds used in drug discovery operations. By integrating the flow of information and research materials across a wide variety of robotics and discovery automation equipment, EMAX Substance Manager helps discovery organizations optimize the productivity of their people, materials, equipment, and facilities. The EMAX software will be implemented in the Discovery wing of Procter & Gamble's brand new Health Care Research Center, located outside of Cincinnati, OH. The 1.3 million square foot Health Care Research Center is dedicated to the discovery and development of prescription and over-the-counter drugs over-the-counter drug A therapeutic agent that does not require a prescription, which the FDA feels can be safely self-prescribed by non-physicians. Cf Prescription drug, Under-the-counter. and health care products. The center serves as the hub of Procter & Gamble's global research and development network, which includes facilities in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. , Europe, Asia and Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. . The implementation of EMAX Substance Manager will be the second major deployment of EMAX software within Procter & Gamble. Last year Procter & Gamble completed the global implementation of EMAX Reagent reagent /re·a·gent/ (re-a´jent) a substance used to produce a chemical reaction so as to detect, measure, produce, etc., other substances. re·a·gent n. Manager to streamline the management of the commercially acquired and inventoried reagents used in Procter & Gamble's research. "We are pleased and proud that Procter & Gamble has again selected EMAX to provide a critical component of their e-Research infrastructure," said Jeb Connor, president of EMAX Solutions. "In a marketplace where time-to-market demands are accelerating, research organizations face tremendous pressure to streamline core processes and procedures, and to maximize time spent on discovery and innovation." About EMAX Solutions Based near Philadelphia, EMAX Solutions, a SciQuest company, is a leading provider of electronic research asset management and planning solutions designed to optimize pharmaceutical drug research operations and expedite ex·pe·dite tr.v. ex·pe·dit·ed, ex·pe·dit·ing, ex·pe·dites 1. To speed up the progress of; accelerate. 2. drug discovery, a domain expert in drug discovery work processes and technologies, and a leading innovator of software and Internet supply chain solutions for life science research organizations. EMAX's e-Research software platform unites scientists, research managers and suppliers into a collaborative e-service network enabling on-demand research enterprise-wide management of the substances and reagents that enable high throughput drug discovery. By eliminating the traditionally time-consuming search for research materials, EMAX enables scientists to focus on lead discovery and decreases the cost per lead by enabling capacity and throughput optimization optimization Field of applied mathematics whose principles and methods are used to solve quantitative problems in disciplines including physics, biology, engineering, and economics. throughout the discovery operation. EMAX software is in use at many of the world's leading research organizations, including Aventis, Bristol Meyers Squibb, Roche, Schering-Plough, Procter & Gamble, Amgen, Chiron, and Kodak. Additional information about EMAX can be found at www.emax.com. About SciQuest SciQuest is a builder and operator of private marketplaces and supply chain solutions exclusively focused on leading research enterprises and their supplier partners worldwide. Its unbiased position and domain expertise make SciQuest the best qualified to make e-commerce work for science through enabling technologies, supply chain solutions and e-services. The company's proven technology and back-office infrastructure can be utilized independently or integrated with leading software vendors and supplier systems to unite science, information and technology. SciQuest's solutions, including the EMAX electronic research asset management and planning solutions, enhance innovation and improve operational effectiveness. Headquartered in Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C., the company has North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. offices in Mountain View, Calif.; Plainview, N.Y.; and Philadelphia; and European offices in London, Paris and Walldorf, Germany. For more information about SciQuest.com, please visit www.sciquest.com or call +1-919-659-2100 (USA) or +49 (0) 6227-382240 (Walldorf). About Procter & Gamble Procter & Gamble sells 300 brands to nearly five billion consumers in more than 140 countries. Pharmaceuticals are an important part of P&G's overall health care business. In pharmaceuticals, P&G is focusing on innovative therapies in the bone health, cardiac and anti-infective areas. P&G's current pharmaceutical brands include Actonel, Didronel, Asacol and Macrobid. EMAX is a registered trademark of EMAX Solutions, a SciQuest company. SciQuest and SciQuest..com are trademarks of SciQuest.com Inc. All other trademarks are the property of their respective holders. Statements in this press release that are not historical facts are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. For such statements, the Company claims the protection of the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The potential risks and uncertainties associated with these forward-looking statements could cause actual results to differ materially from those presented herein, and the reported results should not be considered as an indication of future performance. Factors that could cause actual results to differ from those contained in the forward-looking statements include, among others, the Company's ability to successfully market the SciQuest.com brand, increase transaction volume, attract and retain a broad range of purchasers and suppliers, to effectively add additional products to its e-commerce database and to otherwise operate efficiently and cost effectively. These and other risk factors are discussed in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion